All In Biotech

BLA 125486 · Genentech

Gazyva

Obinutuzumab · Injection · CD20-directed Cytolytic Antibody

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Nov 1, 2013

Approved uses

10

Original approval plus efficacy supplements

Registered trials

351

48 Phase 3, 94 recruiting

FAERS reports

16,929

14,235 serious, 2,206 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor HBV-positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation [see Warnings and Precautions (5.1) ] . Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients receiving GAZYVA [see Warnings and Precautions (5.2) ] . WARNING: HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Hepatitis B Virus (HBV) reactivation, in some cases...

What it is approved for

From the label in effect Oct 1, 2026.

GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). ( 1.1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma (FL)who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1.2 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1.2 , 14 ) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy ( 1.3 , 14 ) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. ( 1.4 , 14 ) 1.1 Chronic Lymphocytic Leukemia (CLL) GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. 1.2 Follicular Lymphoma (FL) GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen . GAZYVA, in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, is indicated for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma . 1.3 Lupus Nephritis (LN) GAZYVA is indicated for the treatment of adult patients with active lupus nephritis who are receiving standard...

Mechanism: Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, obinutuzumab mediates B-cell lysis through (1) engagement of immune effector cells, (2) by directly activating intracellular death signaling pathways (direct cell death), and/or (3) activation of the complement cascade. The immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis. As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 13, 2026 Supplement 44 · Efficacy · priority review LabelLetter
  • Sep 25, 2026 Supplement 43 · Efficacy · priority review OrphanLetterLabel
  • Oct 17, 2025 Supplement 38 · Efficacy LabelLetter
  • Oct 17, 2025 Supplement 37 · Efficacy Breakthrough therapyLabelLetterLetter
  • Feb 14, 2022 Supplement 29 · Efficacy OrphanLetterLabel
  • Mar 27, 2020 Supplement 25 · Efficacy · priority review OrphanLetterLabel
  • Nov 16, 2017 Supplement 17 · Efficacy · priority review OrphanLabelLetter
  • Feb 26, 2016 Supplement 13 · Efficacy · priority review OrphanLabelLetter
  • Dec 24, 2014 Supplement 9 · Efficacy OrphanLetter
  • Nov 1, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanOtherLabelReview
1 products under this application
  • GAZYVA · OBINUTUZUMAB 1000MG/40ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Obinutuzumab" as an intervention, any sponsor and status, largest first.

All 351 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,999
  • neutropenia1,407
  • covid-191,094
  • febrile neutropenia1,049
  • pyrexia1,027
  • thrombocytopenia963
  • disease progression961
  • infusion related reaction882
  • pneumonia805
  • anaemia737
  • infection625
  • atrial fibrillation606

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20112
201219
2013122
2014410
2015375
2016689
2017850
20181,074
2019950
20201,195
20211,177
20222,314
20232,103
20242,473
20251,689
20261,487

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gazyva (Obinutuzumab)

2024 spending

$8.6M

Beneficiaries

210

766 claims

Per beneficiary

$40,972

$199.72 per unit

View as table
YearSpending
2020$1,888,807
2021$2,264,298
2022$3,974,197
2023$5,744,762
2024$8,604,069

Part B: Gazyva (Obinutuzumab) · HCPCS J9301

2024 spending

$184M

Beneficiaries

5,252

26,537 claims

Per beneficiary

$34,943

2024 ASP limit $72.32 per unit

View as table
YearSpending
2020$132,788,036
2021$137,669,767
2022$138,720,200
2023$162,395,517
2024$183,518,022

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 216 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.